Cell Line News and Research

RSS

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells.

22 Apr 2015

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015.

22 Apr 2015

James Shapiro's latest research could soon mark new standard for diabetes treatment

James Shapiro, one of the world's leading experts in emerging treatments of diabetes, can't help but be excited about his latest research. The results he says, could soon mark a new standard for treatment--not only in diabetes, but in several other diseases as well.

22 Apr 2015

Novel treatment strategy targets treatment-resistant CML

Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors.

20 Apr 2015

New combination therapy holds promise for treating HER2-positive breast cancer

Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the therapy.

10 Apr 2015

Stem cell disease model reveals how tumor suppressor may drive bone cancer

Using induced pluripotent stem cells (iPSCs), a team led by Mount Sinai researchers has gained new insight into genetic changes that may turn a well known anti-cancer signaling gene into a driver of risk for bone cancers, where the survival rate has not improved in 40 years despite treatment advances.

10 Apr 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

New technology developed to determine resistance to rabies virus

Researchers at Texas A&M AgriLife Research have developed a new technology to determine sensitivity or resistance to rabies virus.

20 Mar 2015

Gentronix signs three-year technology access deal with SIMM

UK based Gentronix Limited, the specialist genetic toxicology company, today announced it has signed a three year technology access deal with one of China's most prestigious research intensive institutes, Shanghai Institute Materia Medica, Chinese Academy of Sciences.

18 Mar 2015

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Sigma-Aldrich Corporation today announced that SAFC Commercial, its custom manufacturing services business unit, has entered a commercial sales and service contract with leading biopharmaceutical company, BeiGene.

11 Mar 2015

Scientists design a promising vaccine for herpes viruses

Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine.

9 Mar 2015

Johns Hopkins scientists identify genetic pathway that may spur cancer cell growth in children

Working with cells taken from children with a very rare but ferocious form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of other genes and may spur cancer cell growth and resistance to anticancer treatment.

24 Feb 2015

23andMe granted FDA approval to market direct-to-consumer genetic test under novel device classification

23andMe, Inc., the leading personal genetics company, today announced that it has been granted authority by the U.S. Food and Drug Administration (FDA) to market the first direct-to-consumer genetic test under a regulatory classification for novel devices.

20 Feb 2015

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Inflammatory bowel diseases (IBDs), including Crohn disease and ulcerative colitis, are hard to completely cure. Globally, IBDs affect more than 4 million people, today. However, Professor Soichi Tanabe (Graduate School of Biosphere Science, Hiroshima University) and his collaborators have demonstrated that 10-hydroxy-cis-12-octadecenoic acid (HYA), a gut microbial metabolite of linoleic acid, has a suppressive effect on intestinal inflammation.

19 Feb 2015

PKC enzymes categorized as cancer promoters are actually tumor suppressors

Upending decades-old dogma, a team of scientists at the University of California, San Diego School of Medicine say enzymes long categorized as promoting cancer are, in fact, tumor suppressors and that current clinical efforts to develop inhibitor-based drugs should instead focus on restoring the enzymes' activities.

23 Jan 2015

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

7 Jan 2015

Johns Hopkins scientists use genome editing technology to alter human stem cells

A powerful “genome editing” technology known as CRISPR has been used by researchers since 2012 to trim, disrupt, replace or add to sequences of an organism’s DNA.

6 Jan 2015

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.

16 Dec 2014

Centenary researchers find potential way to stop spread of tumors

By blocking a widespread enzyme, Centenary researchers have shown they can slow down the movement of cells and potentially stop tumours from spreading and growing.

16 Dec 2014

Cell Line News and Research

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

James Shapiro's latest research could soon mark new standard for diabetes treatment

Novel treatment strategy targets treatment-resistant CML

New combination therapy holds promise for treating HER2-positive breast cancer

Stem cell disease model reveals how tumor suppressor may drive bone cancer

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

New technology developed to determine resistance to rabies virus

Gentronix signs three-year technology access deal with SIMM

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Scientists design a promising vaccine for herpes viruses

Johns Hopkins scientists identify genetic pathway that may spur cancer cell growth in children

23andMe granted FDA approval to market direct-to-consumer genetic test under novel device classification

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

PKC enzymes categorized as cancer promoters are actually tumor suppressors

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

Johns Hopkins scientists use genome editing technology to alter human stem cells

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

Centenary researchers find potential way to stop spread of tumors

Automated colony picking: Comparing technologies for efficient clone screening eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News